Your current seizure medicines stay the same while researchers study whether adding an investigational medication may help reduce the number of focal seizures you experience. Take your time, learn more, and decide what feels right for you.
Taking part is your choice. You can leave the study at any time.
Condition
Epilepsy
Who it's for
18 years and older
Visits
Multiple visits over approximately 5–6 months
Time commitment
26 weeks
Study format
In-person study with regular follow-up visits
Study treatment
Provided, free to you
Compensation
Travel support may be available
Your privacy
Kept private and secure
Eligibility
If you have been diagnosed with this condition, you may be eligible to take part. Here is a simple guide to who can join.
These are general guidelines. The study team confirms who can join after a short, friendly check.
In plain words
This study is evaluating whether adding an investigational medication called XEN1101 to your current epilepsy treatment may help reduce focal seizures in adults whose seizures are not fully controlled with existing medicines. There are no surgeries or implants involved. The study medication is a once-daily capsule taken by mouth, along with routine health checks, seizure tracking, and scheduled clinic visits. While benefits cannot be guaranteed, you may gain access to a potential new treatment option and receive additional support from the study team. Your participation could also help improve future treatment options for others living with epilepsy.
The challenge today
Many adults living with focal epilepsy continue to have seizures even while taking one or more anti-seizure medications. Researchers are looking for new treatment options that may help improve seizure control.
What researchers hope to learn
Researchers want to understand whether adding the investigational medication XEN1101 to existing epilepsy treatments can safely reduce the number of focal seizures compared with a placebo.
How this study treatment may help
If XEN1101 is effective, it may help some people experience fewer seizures and improve their day-to-day quality of life. However, benefits cannot be guaranteed, and not everyone will receive the investigational medication during the study.
The study team will review your medical history, current medications, and seizure history to confirm whether the study is a good fit for you.
You will continue taking your regular anti-seizure medications and be randomly assigned to receive either the investigational medication XEN1101 or a placebo capsule once daily.
After the treatment period ends, you may choose to join a separate long-term extension study. If you do not continue, you'll attend follow-up visits
1.
Visit the study team on the scheduled dates so they can check how you are doing.
Follow the simple instructions the team gives you for the study treatment.
Note how you feel so the team understands your experience.
Answer a few easy questions about your health and well-being.
The study team will walk you through every possible before you decide. You will have time to ask questions.
Travel support may be available
No. You do not need insurance to take part, and study-related care is provided at no cost to you.
Often yes, but it depends on the study. Share your full medication list with the study team and they will guide you.
Yes. Taking part is your choice, and you can stop at any time for any reason, without affecting your regular care.
You can call or email the study team any time. There is no such thing as a question that is too small.
Yes. Your information is kept private and secure, and only approved people can see your study data.
Tap any word to see a plain-language meaning.
Family members and caregivers are welcome to help you decide. You do not have to do this alone.
Prefer we reach out? Request a callback at a time that works for you.
Xenon Pharmaceuticals
A Phase 3 study evaluating XEN1101 added to existing anti-seizure medications in adults with primary generalized tonic-clonic seizures. Study medication is provided at no cost.
Epilepsy eligibility
Select any one
